Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01636687 · ClinicalTrials.gov registry record · Phase 3
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 182
- Enrollment target
NCT01636687 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 182 participants.
The verdict
NCT01636687, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 182 participants
- Enrollment target
Study Summary
The purpose of this study was to demonstrate efficacy of autoinjector administered secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.
Interventions
- DRUG Placebo
- DRUG Secukinumab 150mg
- DRUG Secukinumab 300mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2012-10-17 |
| Est. Completion | 2016-10-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01636687
The ClinicalTrials.gov registry entry for NCT01636687 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 182 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01636687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01636687 about?
NCT01636687 is a clinical study titled "Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)". The purpose of this study was to demonstrate efficacy of autoinjector administered secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.
What is the current status of trial NCT01636687?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 182 participants. The study started on 2012-10-17. Estimated completion is 2016-10-27.
What interventions are being tested in trial NCT01636687?
The interventions under investigation include: Placebo (DRUG), Secukinumab 150mg (DRUG), Secukinumab 300mg (DRUG).
Who is sponsoring clinical trial NCT01636687?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.